CTOs on the Move

AMPAC Fine Chemicals

www.ampacfinechemicals.com

 
AMPAC Fine Chemicals (AFC) manufactures active pharmaceutical ingredients (APIs) and registered intermediates for customers in the pharmaceutical industry. Our integrated facilities are located in Rancho Cordova, California, approximately 20 miles east
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Advanced Vision Therapies

Advanced Vision Therapies is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Standard Bio

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Melinta

Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

Cadent Therapeutics

Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease.

Aldevron

Aldevron provides contract manufacturing and scientific services. We specialize in plasmid DNA, protein production, and antibody generation. PLASMID DNA PRODUCTION With the successful completion of over 50,000 projects, we have developed unsurpassed expertise in plasmid manufacturing. Using proprietary technology, Aldevron manufactures DNA for a wide range of research, preclinical, clinical, and diagnostic applications (1 mg to 100 g). PROTEIN PRODUCTION Aldevron offers a wide range of protein services including host cell optimization, expression screening, process development, contract production, enzyme and antibody assay design, and more. Proteins produced by Aldevron are used for a wide range of agriculture and biomedical applications from research grade to full cGMP. ANTIBODY GENERATION GENOVAC Antibody Technology supports all project types from reagent antibodies to diagnostic and therapeutic applications with high success rates. Based on many years of experience, our immunization technology has been developed to cater for all protein targets where other methods have failed (including e.g. GPCRs). Our custom antibodies have been validated in over 130 publications and patents for more than 500 clients worldwide. Additional services include antibody processing, production, labeling, characterization and sequencing.